31m
Zacks Investment Research on MSNPfizer (PFE) Down 1.9% Since Last Earnings Report: Can It Rebound?A month has gone by since the last earnings report for Pfizer (PFE). Shares have lost about 1.9% in that time frame, outperforming the S&P 500. Will the recent negative trend continue leading up to ...
Patent Trial and Appeal Board (PTAB) docket entries indicate that the PTAB has invalidated all challenged claims of Moderna’s ...
As part of a global web of patent litigation over COVID-19 vaccines and mRNA technology, Pfizer and its partner BioNTech ...
Moderna's legal win boosts stock but highlights mRNA technology struggles. Discover why MRNA stock may not sustain long-term ...
"We are currently engaging with market participants," a spokesperson for South Africa's Competition Commission told Reuters, declining to provide details. USAID cuts put tuberculosis response in peril ...
Pfizer and BioNTech have convinced a U.S. Patent Office tribunal that two patents Moderna accused Pfizer-BioNtech of ...
German biotech major BioNTech (Nasdaq: BNTX) has suffered a blow as it seeks to add new revenue streams beyond its COVID-19 ...
The US Patent Trial and Appeal Board handed a massive victory to Pfizer (NYSE: PFE) and BioNTech (Nasdaq: BNTX) on Wednesday, ...
Shares in Chinese e-commerce giant Alibaba closed 8.4% higher in Asian trading hours on Thursday, as investors cheered news ...
Moderna (NASDAQ:MRNA) shares jumped 16% on Wednesday, March 5, following a favorable German court decision that determined ...
It has been five years since the World Health Organisation (WHO) declared COVID-19 a pandemic in March 2020 a decision that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results